pipeline-prospector-insert-v1
X

Find Approved Oncology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tisagenlecleucel

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novartis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 28, 2020

            Details:

            Novartis has entered into an agreement with Cell Therapies to manufacture Kymriah at their production facility within the Peter MacCallum Cancer Centre in Melbourne.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daratumumab

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Janssen Biotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 22, 2020

            Details:

            The license agreement terms for Janssen Biotech, Inc. to develop, manufacture and market DARZALEX under the exclusive worldwide license.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Polatuzumab Vedotin

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Roche

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding January 21, 2020

            Details:

            Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ technology. It was developed and is commercialized by Roche/Genentech.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avapritinib

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Blueprint Medicines

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 17, 2020

            Details:

            With nationwide distribution of AYVAKIT, PANTHERx establishes a formidable presence in the precision oncology space.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aldesleukin

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Iovance Biotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 14, 2020

            Details:

            Proleukin will be made available by Clinigen in bulk supply over the course of a two-year period, ensuring that Iovance has uninterrupted access to Proleukin to continue ongoing clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Triptorelin

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Knight Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 08, 2020

            Details:

            The agreement grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada.